Tag: Dual agonist

Tirzepatide is a groundbreaking medication that is the first and only dual GIP and GLP-1 receptor agonist approved for managing type 2 diabetes and obesity. This means **tirzepatide is not a GLP2**; it mimics two different incretin hormones to achieve its powerful therapeutic effects.

In a recent head-to-head clinical trial published in the *New England Journal of Medicine*, participants with obesity treated with tirzepatide achieved significantly greater weight reduction than those treated with semaglutide. This has led many to question: **Why is tirzepatide better than semaglutide?** The answer lies in the pharmaceutical differences and the powerful effects seen in clinical results.

In clinical trials, Zepbound users achieved significant weight reduction, with some losing over 20% of their body weight, by leveraging its unique dual-agonist mechanism. This injectable medication contains the active ingredient tirzepatide, and unlike earlier single-hormone therapies, it targets two key pathways for appetite and glucose control.